Author: admin

“Key players in the high-throughput screening (HTS) market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Trading AG (Switzerland)”

High-Throughput Screening (HTS) Market in terms of revenue was estimated to be worth $25.7 billion in 2023 and is poised to reach $44.5 billion by 2028, growing at a CAGR of 11.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global high-throughput screening (HTS) market is expected to grow at a CAGR of 11.6% during the forecast period. The growth of this market is driven by increasing R&D spending in the HTS market. Increased R&D spending can serve as a driving force for the HTS market due to expanded drug discovery efforts, a focus on personalized medicine, technological advancements, and collaborative research efforts.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

The consumables segment accounted for the largest share, by application in the high-throughput screening (HTS) market in 2022.

On the basis type of product & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software. In 2022, consumables accounted for the largest share of the high-throughput screening market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research.

The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening (HTS) market in 2022.

Based on application, the high-throughput screening market is categorized into drug discovery, biochemical screening, life sciences research, and other applications. The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2022. The key factor driving this segment’s growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.

North America was the largest regional market for high-throughput screening in 2022.

Geographically, the high-throughput screening market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In 2022, North America accounted for the largest share of the high-throughput screening market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the increasing prevalence of diseases, rising pharmaceutical R&D expenditure, and the presence of major players in the region are factors driving the growth of the HTS market in this region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950

High-Throughput Screening (HTS) Market Dynamics:

Drivers:

1. The growing adoption of open innovation models in pharmaceutical & biotechnology companies
2. Government funding and venture capital investments
3. Increasing R&D spending
4. Technological advancements in the HTS market

Restraints:

1. The capital-intensive nature of HTS instruments
2. Complexities in assay development

Opportunities:

1. Emerging markets
2. Growing applications in stem cell research

Challenges:

1. The dearth of skilled operators

Key Market Players:

Key players in the high-throughput screening (HTS) market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Trading AG (Switzerland), AXXAM S.p.A (Italy), Promega Corporation (US), Bio-Rad Laboratories, Inc.(US), Promega Corporation (US), Hamilton Company (US), Corning Incorporated (US), Charles River Laboratories (US), Lonza (Switzerland), REPROCELL Inc. (Japan), Aurora Biomed (Canada), BMG LABTECH (Germany), DIANA Biotechnologies, s.r.o. (Czech Republic), NanoTemper Technologies GmbH (Germany), Creative Biolabs (US), Biomat Srl (Italy), HighRes Biosolutions (US), Cyclica Inc. (Canada), Crown Bioscience (US), and Sygnature Discovery (UK).

Recent Developments:

• In February 2023, Agilent Technologies, Inc. launched the on-deck thermal cycler that integrates with the Agilent Bravo NGS automated liquid handling platform.
• In February 2023, PerkinElmer Inc. launched the Multimode Plate Reader for high-throughput screening (HTS) applications and to accelerate drug discovery efforts.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: High-Throughput Screening (HTS) Market worth $44.5 billion by 2028

“Some of the leading players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US)”

Biomarkers Market in terms of revenue was estimated to be worth $59.1 billion in 2023 and is poised to reach $104.0 billion by 2028, growing at a CAGR of 12.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors driving growth in the market include extensive R&D efforts by leading participants, increasing adoption of biomarkers in drug discovery, the growing importance of companion diagnostics, increasing burden of cancer worldwide, growing funding activities for biomarker research and product innovations, and strategic alliances in biomarkers discovery.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43

The Cancer segment accounted for the largest share of the disease indication segment in the biomarkers market in 2022.

On the basis of disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2022, the cancer segment accounted for the largest share of the biomarkers market. Factor responsible for the large share of this segment can be attributed to the increasing burden of cancer and growing prevalence of the disease across the globe.

In 2022, in the biomarkers market, safety biomarkers accounted for the largest share of the by type segment.

Based on the type, the biomarkers market is divided into validation biomarkers, efficacy biomarkers, and safety biomarkers. The safety biomarkers segment accounted for the biggest share in the biomarkers market in 2022. Factors responsible for the growth in segment includes, increasing awareness in the population with growing diseases such as cancer, cardiovascular disease, and kidney disease led to a large market share for safety biomarkers in the global biomarkers market.

In 2022, the Asia Pacific region is the fastest-growing region of the biomarkers market

In 2022, the Asia Pacific region accounted for the fasted growing region of the biomarkers market. Factors responsible for the growth of this segment is primarily due to the growing use of biomarkers for diagnostic purposes, the increasing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=43

Biomarkers Market Dynamics:

Drivers:

1. Growing importance of companion diagnostics
2. Increase in global prevalence of cancer
3. Increase in funds and grants for biomarker research
4. Continuous product innovations

Restraints:

1. High capital investments and lengthy timelines for biomarker development

Opportunities:

1. Personalized medicine
2. Emerging economies

Challenges:

1. Challenges associated with biomarker validation
2. Technical issues related to sample collection and storage

Key Market Players:

Some of the leading players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=43

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biomarkers Market worth $104.0 billion in 2028

“The Asia Pacific market is expected to witness the highest growth from 2022 to 2027. There is a growing need to implement and integrate medical devices and HCIT solutions in Asia to provide patients with cost-effective and quality clinical care. As a result, many global HCIT companies are investing in the Asian market to capitalize on the growing opportunities.”

Infection Surveillance Solutions Market in terms of revenue was estimated to be worth $577 million in 2022 and is poised to reach $1,100 million by 2027, growing at a CAGR of 13.8% from 2022 to 2027 according to a new report by MarketsandMarkets™. The increasing prevalence of hospital acquired infections (HAI), increasing number of surgeries, growing geriatric population and chronic diseases, and escalating healthcare expenditure is fueling the demand for infection surveillance solutions. The new technology trends in cloud-based and AI integrated software for infection surveillance and control is creating numerous opportunities for solution providers. Furthermore, Emerging economies such as India, China, Brazil, Russia, and countries in Latin America and Southeast Asia are expected to provide significant growth opportunities owing to public pressure to improve the quality of hospital care, the increased cost of HAIs in healthcare systems, the emergence of multi-drug-resistant microorganisms, and the initiatives of government.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21857517

Nursing homes segment is expected to be the largest infection surveillance solutions market for long-term care facilities, by type, during the forecast period

Based on type, the infection surveillance solutions market for long-term care (LTC) facilities is segmented into nursing homes, skilled nursing facilities, and assisted living facilities. The infection surveillance software segment accounted for the largest share of the infection surveillance solutions market. The large share of this segment is primarily attributed to the high prevalence of HAIs in nursing homes and the increased adoption of infection surveillance solutions in these settings.

The hospital segment, by end user, is expected to be the largest and fastest growing infection surveillance solutions market during the forecast period

The infection surveillance solutions market, based on end user, is segmented into hospitals, long-term care facilities, and other end users. The hospitals segment accounted for the largest share of the infection surveillance solutions market and witness the highest growth during the forecast. The high incidence of HAIs, and the resulting cost burden on stakeholders, have driven the adoption of infection control products and services in hospitals. Furthermore, the large patient volume, and the increasing cases of surgical site infections (SSIs) are also driving the growth of the market. The most common HAIs reported in hospitals are central line-associated bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant enterococci bloodstream infections, clostridium difficile infections, and SSIs.

Asia Pacific region is expected to register the highest CAGR in the infection surveillance solutions market during the forecast period

The Asia Pacific market is expected to witness the highest growth from 2022 to 2027. There is a growing need to implement and integrate medical devices and HCIT solutions in Asia to provide patients with cost-effective and quality clinical care. As a result, many global HCIT companies are investing in the Asian market to capitalize on the growing opportunities. The growing patient volume and the rising need for accurate and timely tracking and monitoring of diseases will fuel the growth of the infection surveillance solutions market in Asia Pacific.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=21857517

Infection Surveillance Solutions Market Dynamics:

Drivers:

1. Growing global prevalence of COVID-19
2. Increasing prevalence of hospital-acquired infections
3. Increasing adoption of antimicrobial stewardship programs
4. Increasing number of surgeries
5. Growing geriatric population and the increasing incidence of chronic diseases
6. Growing investments to improve healthcare systems

Restraints:

1. High cost of deployment for small healthcare organizations
2. Reluctance among medical professionals to adopt advanced healthcare IT solutions

Opportunities:

• Increasing consolidation in the healthcare industry
• Cloud-based software solutions
• Emerging markets

Challenges:

1. Shortage of skilled healthcare IT professionals
2. Data security concerns

Key Market Players:

To enable an in-depth understanding of the competitive landscape, the report includes the profiles of some of the top players in the global infection surveillance solutions market. These include including Becton, Dickinson and Company (US), Premier, Inc. (US), Wolters Kluwer N.V. (Netherlands), Cerner Corporation (US), Baxter International Inc. (US), GOJO Industries, Inc. (US), Clinisys (US), Deb Group Ltd. (UK), BioVigil Healthcare Systems (US), RLDatix (UK), Merative (US), Vecna Technologies, Inc. (US), VigiLanz Corporation (US), Ecolab (US), and Harris Healthcare (US). The leading players are trying to establish themselves in the markets of developed countries and are adopting various strategies such as product launches/enhancements, expansions, agreements, partnerships, collaborations, sales contracts, investments, joint ventures, and acquisitions to increase their respective market shares.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=21857517

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/infection-surveillance-solution-market-21857517.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Infection Surveillance Solutions Market worth $1,100 million by 2027

“North America accounted for the largest share of breast lesion localization market in terms of value during forecast period.”

According to the new market research report “Breast Lesion Localization Market by Type (Wire, Radioisotope (ROLL,RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User Preference Survey (Selection Criteria, Replacement Trend) – Global Forecast to 2026″, published by MarketsandMarkets™, the global is expected to reach USD 305 million by 2026 from USD 244 million in 2021, will grow at a CAGR of 4.6% during the forecast period.

Browse in-depth TOC on “Breast Lesion Localization Market”

175 – Tables

49 – Figures

238 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=35768623

The reasons such as growing incidence of breast cancer, growing ageing population and the rising awareness on the early detection of breast cancer contributes to the growth of breast lesion localization market. However, uncertainty in regulatory approval procedures can restrain the growth of the market during the forecast period.

The impact of the COVID-19 pandemic and the lockdown it triggered is clearly visible in various industries, including the breast lesion localization market. The overall growth of various sectors has been heavily impacted, specifically in countries with a high incidence rate of COVID-19, such as China, the US, and several European countries (Russia, Italy, and Spain, among others). While industries such as oil & petroleum, aeronautics, and mining are experiencing a steep fall in revenue, the healthcare, biotechnology, and pharmaceutical industries are optimizing this situation to serve a maximum number of patients and healthcare professionals.

The breast biopsy market witnessed a loss of business, and the trend continued till December 2020. Unfavorable changes in regulations and guidelines are hampering the growth of this industry. Initially, the breast lesion localization market was affected due to the changed protocols to ensure social distancing for limiting the spread of the virus. There was an overall restructuring of breast cancer care in most countries and regions to limit hospital admissions and therapy-induced immune-related complications. Major regulatory authorities across the globe (such as the CDC, the WHO, the MHRA, the TGA, and the EMA) have identified that breast cancer patients are at greater risk of COVID-19 infection than healthy adults. Thus, screening, diagnostic exams, and surgical procedures are being restricted or postponed at hospitals and breast centers, especially in the case of lower-risk patients, considering that most screening and localization procedures require very close contact between patients and caregivers. Moreover, patients are also less likely to seek consultation during the COVID-19 pandemic to avoid visiting hospitals or care center premises. This caused disruption in the breast cancer diagnosis as well as treatment market in 2020.

In terms of value, the wire localization segment accounted for the largest share of the breast lesion localization market in 2020.

Based on type, the market is segmented into wire localization, radioisotope localization, magnetic localization, electromagnetic localization, and other localization methods. The wire localization segment accounted for the largest share of the market in 2020. The appropriate localization of abnormal tissues, the minimum removal of normal tissues, minimum scarring, and the availability of reimbursement for breast lesion localization devices are the major factors driving the growth of the wire localization segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=35768623

Radio-guided occult lesion localization (ROLL) segment accounted for a largest share of the radioisotope localization market in 2020

Radioisotope localization is used for preoperative nonpalpable lesion localization during breast cancer surgeries as well as for sentinel lymph node mapping in cancer staging. By type, the radioisotope localization methods market is segmented into radio-guided occult lesion localization (ROLL) and radioactive seed localization (RSL). Radio-guided occult lesion localization (ROLL) segment accounted for a largest share of the breast lesion localization market in 2020.

In 2020, the Breast Biopsy segment accounted for a largest share of the market.

Based on usage, the breast lesion localization methods market is segmented into Breast Biopsy and Breast Conservation (Lumpectomy). In 2020, the Breast Biopsy segment accounted for a largest share of the breast lesion localization market. The factors driving the growth of the market are the growing incidence of breast cancer, the rising number of breast cancer screening programs, improved reimbursement scenarios, increased awareness of early detection of breast cancer, and greater demand for minimally invasive and non-invasive procedures.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=35768623

North America accounted for the largest share of the breast lesion localization market is 2020

The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW).

North America accounted for the largest share of breast lesion localization market in terms of value during forecast period. APAC market is projected to grow at the highest CAGR due to the reasons such as increasing patient population, rising government spending on breast cancer research, increasing healthcare expenditure and increasing awareness about early detection of breast cancer.

Key players in the market Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), MatekMedikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada). Other players in the breast lesion localization market are Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeosrl (Italy), and Medax Medical Devices (Italy).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/breast-lesion-localization-methods-market-35768623.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Lesion Localization Market worth $0.4 billion by 2028

“North America has emerged as the dominant region in the cell-based assays market. The region’s leadership can be attributed to several factors, including a robust pharmaceutical and biotechnology industry, extensive research and development activities, and a favorable regulatory environment.”

Cell based Assays Market in terms of revenue was estimated to be worth $18.9 billion in 2023 and is poised to reach $28.2 billion by 2028, growing at a CAGR of 8.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global cell-based assays market is expected to grow at a CAGR of 8.4% during the forecast period. The market for cell-based assays is experiencing significant growth primarily due to the increasing demand for drug discovery and development, as well as the rising adoption of cell-based assays in this process. Government support and funding for cell-based research initiatives are further contributing to this growth. Additionally, efforts by regulatory authorities, such as the FDA, to reduce reliance on animal-based studies are driving the adoption of cell-based assays.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269

The instruments and software segment accounted for the second largest share, by product and service in the cell-based assays market in 2022.

These sophisticated instruments enable researchers to automate and streamline various aspects of cell-based assays, enhancing efficiency, accuracy, and throughput. Additionally, powerful software platforms provide advanced data analysis, visualization, and integration capabilities, enabling researchers to derive valuable insights from their experiments. The integration of cutting-edge instruments and software solutions into cell-based assays research workflows is revolutionizing the field and propelling the market forward.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the cell-based assays market in 2022. 

The pharmaceutical & biopharmaceutical companies dominated the market in 2022. Pharmaceutical & biopharmaceutical companies are the largest end users of cell-based assays. The demand for cell-based assays in this end-user segment is driven by the growth in the number of R&D activities for the development of new pharma and biotech drugs and therapies coupled with the adoption of cell-based assays in these companies.

The North America region catered the largest share of the cell-based assays market in 2022.

North America has emerged as the dominant region in the cell-based assays market. The region’s leadership can be attributed to several factors, including a robust pharmaceutical and biotechnology industry, extensive research and development activities, and a favorable regulatory environment. Furthermore, the presence of key market players, advanced healthcare infrastructure, and significant investments in drug discovery and development contribute to North America’s strong market position. The region’s emphasis on technological advancements and the adoption of innovative approaches in cell-based assays further solidifies its dominance in the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=119917269

Cell based Assays Market Dynamics:

Drivers:

1. Growing preference for cell-based assays in drug discovery
2. Increasing funding for cell-based research
3. Growth in the number of drug discovery activities

Restraints:

1. High cost of instruments and restrictions on reagent use
2. Lack of infrastructure for cell-based research in emerging economies

Opportunities:

1. Emerging economies
2. Growing risk of pandemics and communicable diseases
3. Application of novel cell-based assays in cancer research

Key Market Players:

Key players in the cell-based assays market include Danaher Corporation (US), Thermo Fisher Scientific (US), Merck (Germany), Becton, Dickinson and Company (US), Lonza (Switzerland), PerkinElmer (US), Charles River Laboratories (US), Eurofins Scientific (France), Enzo Biochem (US), Carna Biosciences (Japan), Cell Biolabs (US), Promega Corporation (US), Cell Signaling Technology (US), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), Pestka Biomedical Laboratories (US), InvivoGen (US), CA3 Biosciences (US), BPS Bioscience (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), and JRS Pharma (Germany).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=119917269

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cell based Assays Market worth $28.2 billion by 2028